NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

NVO

Novo Nordisk ADR

Apr 23 • 12:59PM ET

61.40

Dollar change +1.49
Percentage change 2.49	%

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN PFE SNY BMY GSK

| Held by: AVDE PPH NUGO DFIC APIE OZEM PID RVER DFAI WINN

Scroll to Statements

Index	-	P/E	18.70	EPS (ttm)	3.28	Insider Own	0.01%	Shs Outstand	3.37B	Perf Week	-4.79%
Market Cap	206.56B	Forward P/E	12.79	EPS next Y	4.80	Insider Trans	0.00%	Shs Float	3.36B	Perf Month	-18.49%
Income	14.65B	PEG	0.95	EPS next Q	0.91	Inst Own	10.13%	Short Float	0.44%	Perf Quarter	-23.79%
Sales	42.09B	P/S	4.91	EPS this Y	24.90%	Inst Trans	0.16%	Short Ratio	1.63	Perf Half Y	-48.01%
Book/sh	4.49	P/B	13.69	EPS next Y	21.52%	ROA	26.33%	Short Interest	14.66M	Perf Year	-49.96%
Cash/sh	1.09	P/C	56.54	EPS next 5Y	19.67%	ROE	82.03%	52W Range	57.00 - 148.15	Perf YTD	-28.62%
Dividend Est.	1.98 (3.22%)	P/FCF	19.30	EPS past 5Y	21.74%	ROI	45.25%	52W High	-58.56%	Beta	0.70
Dividend TTM	1.66 (2.70%)	Quick Ratio	0.55	Sales past 5Y	18.58%	Gross Margin	84.67%	52W Low	7.72%	ATR (14)	3.05
Dividend Ex-Date	Mar 31, 2025	Current Ratio	0.74	EPS Y/Y TTM	21.42%	Oper. Margin	44.94%	RSI (14)	38.23	Volatility	3.15% 3.75%
Employees	76302	Debt/Eq	0.72	Sales Y/Y TTM	24.91%	Profit Margin	34.81%	Recom	2.03	Target Price	107.74
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	28.11%	Payout	35.93%	Rel Volume	1.12	Prev Close	59.91
Sales Surprise	7.50%	EPS Surprise	6.56%	Sales Q/Q	29.02%	Earnings	Feb 05 BMO	Avg Volume	9.00M	Price	61.40
SMA20	-5.10%	SMA50	-18.72%	SMA200	-41.12%	Trades		Volume	5,625,784	Change	2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight	$120
Oct-02-23	Initiated	Argus	Buy	$110
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform	$130
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy

Show Previous Ratings

Today 09:45AM	Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly (Seeking Alpha)
09:10AM	Polen Focus Growth Portfolio Q1 2025 Commentary (Seeking Alpha)
08:40AM	Polen Global Growth Portfolio Q1 2025 Commentary (Seeking Alpha)
08:10AM	Polen International Growth Portfolio Q1 2025 Commentary (Seeking Alpha)
08:00AM	10-Year Anniversary Letter: The Rowan Street Story (Seeking Alpha)
07:33AM	Loading…
07:33AM	Eli Lilly Nails Oral GLP-1 Trial-Here's What It Means for LLY (MarketBeat)
06:58AM	Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy? (Zacks)
05:50AM	Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock? (Motley Fool)
05:07AM	Is Eli Lilly Stock a Buy? (Motley Fool)
Apr-22-25 02:07PM	Novo Nordisk (NVO) Is a Good Short-Term Pick, Wealth Manager Says (Insider Monkey)
12:17PM	Why Novo Nordisk Stock Popped Today (Motley Fool)
11:12AM	Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop (Investor's Business Daily)
10:49AM	Novo Nordisk: Be Greedy When Others Are Fearful (Seeking Alpha)
08:42AM	Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time. (Motley Fool)
05:15AM	Down 60%, Is This Growth Stock Too Cheap to Ignore? (Motley Fool)
04:34AM	Loading…
04:34AM	Novo shares down on Eli Lillys positive obesity pill data (Investing.com)
03:50AM	Novo Nordisk Drops on Weight-Loss Study by Rival Lilly (Bloomberg)
Apr-21-25 09:42PM	Is Novo Nordisk A/S (NVO) The Top Falling Stock with Unusual Volume? (Insider Monkey)
05:45PM	Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note (Zacks)
05:27PM	5 Reasons To Buy Eli Lilly (Seeking Alpha)
09:15AM	Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip? (Motley Fool)
09:00AM	Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks)
08:21AM	Novo says its submitted obesity pill for FDA approval (BioPharma Dive)
04:30AM	Did Eli Lilly Just Say Checkmate to Novo Nordisk? (Motley Fool)
04:00AM	Can anything threaten Novo and Lillys obesity market dominance? (Pharma Voice)
Apr-20-25 09:15AM	Selling America, Buying Europe - My Picks (Seeking Alpha)
09:00AM	Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging (Seeking Alpha)
05:21AM	Novo Nordisk: Why I Love Collars, And Why This Stock Is Getting Close (Seeking Alpha)
Apr-19-25 03:23AM	Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy? (Motley Fool)
03:20PM	Loading…
Apr-18-25 03:20PM	Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempics Competition Grows (Barrons.com)
11:46AM	Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing (Barrons.com)
11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:52AM	Novo Nordisk: A Price Too Low To Ignore (Seeking Alpha)
04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:50PM	East 72 Dynasty Trust Q1 2025 Quarterly Report (Seeking Alpha) -7.63%
04:29PM	How Eli Lilly's GLP-1 pill could transform the weight-loss space (Yahoo Finance Video)
04:10PM	Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill (Investor's Business Daily)
02:41PM	Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race (Investing.com)
01:54PM	Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade (Investopedia)
01:45PM	Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results (Seeking Alpha)
12:46PM	Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide (Motley Fool)
12:45PM	Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More (Investopedia)
11:36AM	Wall Street Lunch: Obesity Pill Progress (Seeking Alpha)
11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
10:18AM	Eli Lilly stock soars on positive weight-loss pill results (Yahoo Finance Video)
10:07AM	Novo Nordisk shares slump following Eli Lillys weight-loss pill success (Investing.com)
09:00AM	Eli Lilly Stock Soars on Oral Weight-Loss Drug Trial Results (Investopedia)
08:34AM	Eli Lilly Stock Rockets On Weight-Loss Pill Progress (Investor's Business Daily)
06:45AM	Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch (Benzinga)
Apr-16-25 10:04PM	"I Am a Buyer": Jim Cramer Backs Novo Nordisk (NVO) After Its Sharp Decline (Insider Monkey)
02:37PM	Novo Nordisk A/S (NVO): A Bull Case Theory (Insider Monkey)
10:39AM	The GLP-1 drug shortage is over. Whats next for the compounders? (Pharmaceutical Technology)
10:33AM	Viking Therapeutics Stock Pops But Struggles to Hold Gains (MarketBeat)
07:50AM	A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value (Seeking Alpha)
07:05AM	Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip? (Zacks)
06:05AM	BGY: Underlying Fundamentals Can Be Improved (Seeking Alpha)
Apr-15-25 04:21PM	Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market (Seeking Alpha)
04:20PM	Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts (Benzinga)
02:52PM	Is Novo Nordisk A/S (NVO) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
12:57PM	Pfizer Halts Obesity Pill Development Amid Safety Concerns (Zacks)
11:10AM	Novo Nordisk warns of counterfeit Ozempic injections (TipRanks)
11:05AM	Novo Nordisk warns consumers about counterfeit Ozempic injections (TipRanks)
10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
09:09AM	The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now (Seeking Alpha)
07:15AM	PepsiCo's Valuation Hasn't Been This Low In A Decade - Time To Buy (Seeking Alpha)
Apr-14-25 03:49PM	Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries (Reuters)
03:00PM	Tap Into the Silver Economy Boom With These Aging Demographics Stocks (Zacks)
11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool)
10:55AM	Pfizer just had a big setback in its race for an Ozempic competitor (Quartz)
10:37AM	ABBV vs. MRK: Which Drug Giant is a Better Buy Now? (Zacks)
10:13AM	Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury' (Investopedia)
09:53AM	Pfizer discontinues GLP-1 pill trial, stock trades flat (Yahoo Finance)
Apr-13-25 11:50PM	ClearBridge International Growth ACWI Ex-U.S. Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-11-25 12:23PM	Novo Remade Denmark. Then Came the Stock Selloff. (Barrons.com) +5.75%
12:10PM	Oakmark Global Fund Q1 2025 Commentary (Seeking Alpha)
10:10AM	Harding Loevner International Equity Q1 2025 Commentary (Seeking Alpha)
09:40AM	Here's Why Novo Nordisk (NVO) is a Strong Value Stock (Zacks)
09:06AM	Wall Street Pulls Back on the Weight-Loss Drug Hype (Barrons.com)
03:13AM	Pharmas US manufacturing moment: Where companies are making the biggest moves (Pharma Voice)
03:13AM	Pharmas manufacturing moment: Where companies are making the biggest moves (Pharma Voice)
12:30AM	Harbor International Fund Q4 2024 Commentary (Seeking Alpha)
12:30AM	Harbor International Compounders Fund Q4 2024 Commentary (Seeking Alpha)
12:30AM	Harbor International Compounders ETF Q4 2024 Commentary (Seeking Alpha)
Apr-10-25 11:55PM	Harbor Diversified International All Cap Fund Q4 2024 Commentary (Seeking Alpha) -5.96%
02:37PM	'Carp Special': $100,000 In A 52-Week Low-Quality Portfolio (Seeking Alpha)
12:01PM	Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. (Investor's Business Daily)
08:54AM	Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
08:10AM	Harbor Long-Term Growers ETF Q4 2024 Commentary (Seeking Alpha)
05:00AM	The Zacks Analyst Blog Highlights Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park (Zacks)
Apr-09-25 04:51PM	Top Analyst Reports for Procter & Gamble, Novo Nordisk & PepsiCo (Zacks) +5.67%
03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
12:03PM	Top Stock Movers Now: Delta, Apple, Eli Lilly, and More (Investopedia)
11:15AM	Delta, Walmart, pharmaceutical stocks: Market Minute (Yahoo Finance Video)
10:28AM	Pharma Stocks Sink as Trump Says 'Major' Tariffs Coming to Industry (Investopedia)
10:06AM	Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan (Investor's Business Daily)
10:00AM	5 Top Growth Stocks to Buy in the Stock Market Sell-Off (Motley Fool)
09:51AM	Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs (The Wall Street Journal)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience